PepGen (NASDAQ:PEPG - Get Free Report) had its price target reduced by equities research analysts at HC Wainwright from $14.00 to $8.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 435.12% from the stock's current price.
PepGen Stock Performance
Shares of PEPG stock traded down $0.18 on Thursday, reaching $1.50. The stock had a trading volume of 155,485 shares, compared to its average volume of 829,355. The stock has a market cap of $48.92 million, a P/E ratio of -0.50 and a beta of 1.39. The company has a 50 day simple moving average of $1.41 and a 200 day simple moving average of $2.50. PepGen has a 1 year low of $0.88 and a 1 year high of $19.30.
PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.20). On average, equities research analysts anticipate that PepGen will post -2.73 earnings per share for the current fiscal year.
Insider Activity at PepGen
In related news, CEO James G. Mcarthur acquired 41,500 shares of the business's stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average cost of $1.15 per share, for a total transaction of $47,725.00. Following the purchase, the chief executive officer now owns 103,913 shares in the company, valued at $119,499.95. The trade was a 66.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.20% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new position in PepGen in the 4th quarter worth approximately $26,000. Corton Capital Inc. purchased a new position in PepGen in the 4th quarter worth approximately $68,000. XTX Topco Ltd purchased a new position in PepGen in the 1st quarter worth approximately $25,000. ADAR1 Capital Management LLC purchased a new position in PepGen in the 1st quarter worth approximately $29,000. Finally, JPMorgan Chase & Co. lifted its holdings in PepGen by 289.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 26,611 shares of the company's stock worth $228,000 after purchasing an additional 19,786 shares in the last quarter. 58.01% of the stock is owned by hedge funds and other institutional investors.
About PepGen
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Stories
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
